心臓手術用機器の世界市場-2023年～2030年

概要

心臓手術用機器の世界市場は2022年に21億米ドルに達し、2023-2030年の予測期間中にCAGR 3.4％で成長し、2030年には32億米ドルに達すると予測されています。

心臓手術用機器は、先天性心疾患、不整脈、心臓弁膜症など、多くの心血管疾患の治療に使用されます。心臓手術用機器は、損傷したり詰まったりした弁や動脈を含む心臓の循環系における構造的問題の治癒を支援します。

ペースメーカー、植え込み型除細動器（ICD）、心臓弁、バルーンカテーテル、ステントなどの心臓・血管手術用機器は、心血管疾患の管理・治療に重要な役割を果たしているため、世界の心臓手術用機器市場は近年大きな成長を遂げています。

さらに、技術的進歩の増加、製品の発売、有利な償還政策などの重要な成長促進要因が将来の市場成長をもたらします。Medtronic plc、Terumo Corporation、LivaNova Plc、Abbott Laboratories、Murray Surgical Limited、Boston Scientific Corporationなどのその他の主要企業が、この市場で活発に活動しています。

ダイナミクス

心臓手術用機器の技術進歩

心臓手術用機器は、虚血性心疾患、リウマチ性心疾患、うっ血性心不全、心臓弁膜症など、多くの心血管疾患の治療に使用されています。大手企業による主要な技術的進歩は、市場の成長を促進するのに役立っています。こうした効果的な進歩は、研究の発見を新たな治療法に転換し、何百万人もの心臓病患者のケアを改善するのに役立ちます。

例えば、2023年5月、Robocath社はEuroPCR 2023会議で冠動脈形成術用のR-One+と呼ばれる心臓手術用ロボットシステムを発表しました。このプラットフォームにより、心臓専門医はカテーテル検査室に配置可能な制御コマンドユニットから機器を制御することができます。

さらに、2022年12月、アボット・ラボラトリーズは、最新世代の経カテーテル大動脈弁植え込み（TAVI）システム、ナビトールを発売し、手術リスクが高いか極めて高い重症の大動脈弁狭窄症の患者にも低侵襲デバイスを利用できるようにしました。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

好意的な償還政策が心臓手術用機器市場を押し上げる

償還政策は、手技の複雑さ、使用されるカテーテルの種類、手技中に利用される関連医療資源などの要因を考慮することが多いです。償還政策は、心臓カテーテル治療を実施するために医療提供者に提供される保険や財政的償還のレベルを決定するため、心臓手術用機器市場で重要な役割を果たしています。

例えば、2022年7月のShockwave Medicalによると、2021年初頭にCoronary IVLを発売して以来、Shockwaveは償還に関して深く大きく前進しました。彼らは、外来、ASC、入院患者の設定で償還を得ています。さらに、Coronary Category III CPTコードによる医師への償還の機会もあります。

心臓カテーテル治療の合併症が市場の成長を妨げる

心臓カテーテル治療では血管にカテーテルを挿入するため、血管に損傷を与える可能性があります。これには血管穿孔、解離（血管壁の断裂）、破裂などが含まれます。血管の損傷は出血や血腫形成の原因となり、外科的修復を必要とすることさえあります。

CardioVascular Group, April 2023によると、心臓カテーテル検査に伴う最も一般的なリスクは出血です。手技中、カテーテルを挿入するために小さな切開を行うが、これが出血につながる可能性があります。不整脈と呼ばれる心調律異常は、心臓カテーテル検査中または検査後に起こることがあります。不整脈は、手技中の血流の変化や、カテーテルが心筋とこすれることによって生じることがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 心臓手術用機器の技術進歩
    • 有利な償還政策
  • 抑制要因
    • 心臓カテーテル治療の合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析
• DMIの見解

第6章 COVID-19分析

第7章 製品別

• 心臓手術装置
  • スタビライザー
  • ポジショナー
• 人工心肺装置
  • 動脈カニューレ
  • 静脈カニューレ
  • 酸素供給器
• カテーテル
  • バルーンカテーテル
  • アブレーションカテーテル
  • ドレナージカテーテル
• 灌流用使い捨て用品
  • 動脈フィルター
  • コネクター
  • 血液濃縮器

第8章 手技別

• 冠動脈バイパス術
• 低侵襲手術
• その他

第9章 用途別

• 先天性心疾患
• 冠動脈疾患
• 不整脈
• 心臓弁膜症
• その他

第10章 エンドユーザー別

• 病院
• 心臓センター
• 外来手術センター
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な動向と戦略

第13章 企業プロファイル

• Medtronic Plc
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Terumo Corporation
• LivaNova Plc
• Abbott Laboratories
• Murray Surgical Limited
• Boston Scientific Corporation
• Getinge AB
• Wexler Surgical
• Lepu Medical Technology Co. Ltd.
• Gore Medical Inc.

第14章 付録

Overview

Global Cardiac Surgery Devices Market reached US$ 2.1 billion in 2022 and is expected to reach US$ 3.2 billion by 2030 growing with a CAGR of 3.4% during the forecast period 2023-2030.

Cardiac surgery devices are used in the treatment of many cardiovascular diseases including congenital heart disease, arrhythmias, and heart valve disease. Cardiac surgery devices aid in the healing of structural problems in the circulatory system of the heart including damaged or clogged valves and arteries.

The global cardiac surgery devices market has witnessed significant growth in recent years due to the usage of cardiac and vascular surgery devices such as pacemakers, implantable cardioverter defibrillators (ICDs), heart valves, balloon catheters, and stents as they play a key role in managing and treating cardiovascular diseases.

Furthermore, significant growth drivers such as increasing technological advancements, product launches, and favorable reimbursement policies give rise to future market growth. Significant key players like Medtronic plc, Terumo Corporation, LivaNova Plc., Abbott Laboratories, Murray Surgical Limited, Boston Scientific Corporation, and others are actively operating in the market.

Dynamics

Technological Advancements in Cardiac Surgery Devices

Cardiac surgery devices are used to treat many cardiovascular diseases such as ischemic heart disease, rheumatic heart disease, congestive heart failure, and valvular heart disease. The major technological advancements by major companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with heart diseases.

For instance, in May 2023, Robocath launched a robot system for heart surgery called R-One+, for coronary angioplasties at the EuroPCR 2023 conference. The platform allows the cardiologist to control devices from the control command unit which can be positioned in the catheterization laboratory.

Additionally, in December 2022, Abbott Laboratories launched its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, by making the minimally invasive device available for people with severe aortic stenosis who are at high or extreme surgical risk. Hence, due to the above factors, the market is expected to boost over the forecast period.

Favorable Reimbursement Policies are Boosting the Cardiac Surgery Device Market

Reimbursement policies often consider factors such as the complexity of the procedure, the type of catheter used, and the associated healthcare resources utilized during the procedure. Reimbursement policies play a crucial role in the cardiac surgery device market as they determine the level of coverage and financial reimbursement provided to healthcare providers for performing cardiac catheterization procedures.

For instance, according to Shockwave Medical July 2022, since the launch of Coronary IVL in early 2021, Shockwave has made deep and significant progress on reimbursement. They have reimbursement in the outpatient, ASC, and inpatient settings. In addition, an opportunity for physician reimbursement via Coronary Category III CPT code.

Complications for Cardiac Catheterization Will Hamper the Growth of the Market

Cardiac catheterization involves the insertion of a catheter into blood vessels, which can potentially cause vessel damage. This can include vessel perforation, dissection (tearing of the vessel wall), or rupture. Vessel damage can result in bleeding, hematoma formation, or even require surgical repair.

According to CardioVascular Group, April 2023, the most common risk associated with cardiac catheterization is bleeding. During the procedure, a small incision is made to insert the catheter, and this can lead to bleeding. Heart rhythm abnormalities called arrhythmias can happen during or after cardiac catheterization. These can result from changes in blood flow during the procedure or from the catheter rubbing against the heart muscle.

Segment Analysis

The global cardiac surgery devices market is segmented based on product, procedure, application, end users, and region.

Catheters from the Product Segment Accounted for Approximately 47.2% of the Global Cardiac Surgery Devices Market Share

The catheterization procedure is typically carried out in patients by using various catheters with certain congenital heart defects, such as transposition of the great arteries or pulmonary atresia, where there is an abnormal communication or inadequate blood flow between the atria. The demand for catheters is driven by the increasing incidence of cardiovascular diseases.

For instance, in May 2023, Abbott Laboratories received the approval of the U.S. Food and Drug Administration (FDA) for the company's TactiFlex Ablation Catheter which is sensor-enabled and the world's first ablation catheter with a flexible tip and contact force technology.

Additionally, in May 2022, Medtronic Plc. received approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.

Geographical Penetration

North America Accounted for Approximately 38.5% of the Market Share in 2022

North America has maintained a significant proportion of the cardiac surgery devices market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising number of open heart surgeries performed in the U.S. and technological advancements in cardiac surgery devices.

For instance, according to the Lifespan Health System, there are about 500,000 open heart surgeries performed each year in the United States. It is most often used for complicated procedures, such as coronary artery bypass, or complex procedures to the aorta or the heart itself. Also, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021.

Competitive Landscape

The major global players in the market include: Medtronic Plc., Terumo Corporation, LivaNova Plc., Abbott Laboratories, Murray Surgical Limited, Boston Scientific Corporation, Getinge AB, Wexler Surgical, Lepu Medical Technology Co. Ltd, and Gore Medical Inc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cardiac surgery device market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device implantations, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduced cardiac surgery in many patients suffering from congenital heart defects.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the cardiac surgery device market is expected to be moderately affected over the forecast period.

By Product

• Beating Heart Surgery Systems
  • Stabilizers
  • Positioners

• Cardiopulmonary Bypass Equipment
  • Arterial cannula
  • Venous cannula
  • Oxygenators

• Catheters
  • Balloon catheter
  • Ablation Catheter
  • Drainage Catheter

• Perfusion Disposables
  • Arterial Filters
  • Connectors
  • Hemoconcentrator

• Others

By Procedure

• Coronary Artery Bypass Grafting
• Minimally Invasive Surgery
• Others

By Application

• Congenital Heart Disease
• Coronary Artery Disease
• Arrhythmias
• Heart Valve Disease
• Rheumatic Heart Disease
• Aortic Aneurysm
• Congestive Heart Failure
• Others

By End Users

• Hospital
• Cardiac Centers
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In March 2023, Shockwave Medical launched the new peripheral IVL catheter. The Shockwave L6 catheter is purpose-built to modify calcification in otherwise difficult-to-treat lesions in large peripheral vessels, including the iliac and the common femoral arteries.
• In June 2023, Terumo Aortic launched of the company's global post-approval study (PAS) known as EXTEND for Thoraflex Hybrid, the only frozen elephant trunk (FET) device approved by the US Food and Drug Administration (FDA) for the treatment of patients with complex aortic arch disease.

Why Purchase the Report?

• To visualize the global cardiac surgery devices market segmentation based on product, procedure, application, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global cardiac surgery devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cardiac surgery devices market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Procedure
• 3.3. Snippet by Applications
• 3.4. Snippet by End Users
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Technological advancements in cardiac surgery devices
    • 4.1.1.2. Favorable reimbursement policies
  • 4.1.2. Restraints
    • 4.1.2.1. Complications for cardiac catheterization
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Beating Heart Surgery System
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Stabilizers
  • 7.2.4. Positioners
• 7.3. Cardiopulmonary Bypass Equipment
  • 7.3.1. Arterial cannula
  • 7.3.2. Venous cannula
  • 7.3.3. Oxygenators
• 7.4. Catheters
  • 7.4.1. Balloon catheter
  • 7.4.2. Ablation Catheter
  • 7.4.3. Drainage Catheter
• 7.5. Perfusion Disposables
  • 7.5.1. Arterial Filters
  • 7.5.2. Connectors
  • 7.5.3. Hemoconcentrator

8. By Procedure

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 8.1.2. Market Attractiveness Index, By Procedure
• 8.2. Coronary Artery Bypass Grafting
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Minimally Invasive Surgery
• 8.4. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Congenital Heart Disease
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Coronary Artery Disease
• 9.4. Arrhythmias
• 9.5. Heart Valve Disease
• 9.6. Others

10. By End Users

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.1.2. Market Attractiveness Index, By End Users
• 10.2. Hospitals
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Cardiac Centers
• 10.4. Ambulatory Surgical Centers
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Product Benchmarking
• 12.3. Company Share Analysis
• 12.4. Key Developments and Strategies

13. Company Profiles

• 13.1. Medtronic Plc*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Terumo Corporation
• 13.3. LivaNova Plc
• 13.4. Abbott Laboratories
• 13.5. Murray Surgical Limited
• 13.6. Boston Scientific Corporation
• 13.7. Getinge AB
• 13.8. Wexler Surgical
• 13.9. Lepu Medical Technology Co. Ltd.
• 13.10. Gore Medical Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us